1 – 10 of 50
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes : the STREAM study
(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor : a single- and multiple-dose first-in-human study in healthy participants
(
- Contribution to journal › Article
- 2022
-
Mark
Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease : The BEAMS Randomized Clinical Trial
(
- Contribution to journal › Article
- 2020
-
Mark
The Effect of Cynara scolymus on Blood Pressure and BMI in Hypertensive Patients : A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
(
- Contribution to journal › Article
- 2018
-
Mark
Treatment outcomes and patient-reported quality of life after orthognathic surgery with computer-assisted 2- or 3-dimensional planning : A randomized double-blind active-controlled clinical trial
(
- Contribution to journal › Article
- 2017
-
Mark
Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients
(
- Contribution to journal › Article
-
Mark
Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men
(
- Contribution to journal › Article
-
Mark
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
(
- Contribution to journal › Article
- 2016
-
Mark
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
(
- Contribution to journal › Article
-
Mark
Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses
(
- Contribution to journal › Article